Stocks-SRNE-Sorrento Therapeutics Inc

SRNE Sorrento Therapeutics Inc

1.02 0 (0%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
Invest

Overview

Prev Close1.02
Day's Range 0.9600 - 1.03
52 Week Range 0.7160 - 3.59
Average Volume (3M)11.36M
1-Year Return-68.02%
Beta1.0202
Market Cap481.32M
P/E Ratio
Revenue60.32M
EPS-1.3301
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.722/08/202202/11/202217/01/20231.001.502.002.503.00
Chart times in UTC
Industry Biotechnology
CEO Henry H. Ji, PhD
Employees 799

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2021: Sorrento Therapeutics Inc's revenues increased by 32.31% and amounted to 52.90M. Net income decreased by 36.49% to -429.14M. Net assets decreased by 44.48% to 78.13M and EPS decreased from -1.30 to -1.45.
SRNE's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
55.08%
Net Profit Margin
-861.41%
Operating Margin
-668.99%
Return On Investment
-97.40%
12/21
03/22
06/22
09/22
Total Revenue
13.08M
18.39M
11.46M
17.4M
Gross Profit
8.9M
11.59M
4.72M
8.01M
Operating Income
-104.81M
-96.71M
-91.88M
-110.14M
Net Income
-144.86M
-40.54M
-219.48M
-90.63M